GenMark Q4 Revenues Fall 31 Percent, Beat Analyst Estimates | GenomeWeb

NEW YORK (GenomeWeb News) – GenMark Diagnostics reported after the close of the market on Tuesday that its revenues in the fourth quarter fell 31 percent year over year, but the company still beat the average Wall Street estimate on the top and bottom lines.

The Carlsbad, Calif.-based molecular diagnostics firm reported $6.5 million in total revenues for the three months ended Dec. 31, 2013, compared to $9.4 million in the year-ago fourth quarter and besting the consensus Wall Street estimate of $6.1 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.